Recently, ZS Pharmaceutical announced that the new drug application for Angravir granules, an innovative Class I drug developed by its subsidiary Guangdong ZS Ruicheng Biotechnology Co., Ltd. for the treatment of uncomplicated influenza A in children aged 2 to 11 years, has been formally accepted by the National Medical Products Administration (NMPA).

Onradivir is a small RNA polymerase PB2 protein inhibitor. It can bind to the PB2 subunit by acting as a "cap" structure analog, thereby inhibiting the normal initiation of the RNA polymerase complex replication function. This inhibits multiple functions of the viral life cycle genome, such as transcription and replication, thus achieving an anti-influenza A virus effect.

On May 20, 2025, ondiravir tablets were approved by the National Medical Products Administration for the treatment of adult patients with uncomplicated influenza A. Ondiravir is the world's first innovative drug targeting the PB2 subunit of influenza A virus RNA polymerase, developed under the leadership of Academician Zhong Nanshan of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory .

https://mp.weixin.qq.com/s/Ttwo3tivZLZygTKY371LnA